Compare, Analyse Glenmark Pharma with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs MYLAN (US) - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GLENMARK PHARMA   MYLAN
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
MYLAN
Dec-18
GLENMARK PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs7123,377-   
Low Rs4841,859-   
Sales per share (Unadj.) Rs349.61,554.0-  
Earnings per share (Unadj.) Rs32.842.2-  
Cash flow per share (Unadj.) Rs44.3333.2-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs198.61,681.1-  
Shares outstanding (eoy) m282.17514.50-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.71.7 101.5%   
Avg P/E ratio x18.262.0 29.4%  
P/CF ratio (eoy) x13.57.9 171.5%  
Price / Book Value ratio x3.01.6 193.2%  
Dividend payout %6.10-   
Avg Mkt Cap Rs m168,6251,346,989 12.5%   
No. of employees `00012.035.0 34.4%   
Total wages/salary Rs m20,5610-   
Avg. sales/employee Rs Th8,196.022,843.9 35.9%   
Avg. wages/employee Rs Th1,708.10-   
Avg. net profit/employee Rs Th768.5620.3 123.9%   
INCOME DATA
Net Sales Rs m98,655799,536 12.3%  
Other income Rs m2,0810-   
Total revenues Rs m100,736799,536 12.6%   
Gross profit Rs m15,858206,890 7.7%  
Depreciation Rs m3,259149,705 2.2%   
Interest Rs m3,34638,455 8.7%   
Profit before tax Rs m11,33518,731 60.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,6720-   
Tax Rs m3,756-2,980 -126.1%   
Profit after tax Rs m9,25021,711 42.6%  
Gross profit margin %16.125.9 62.1%  
Effective tax rate %33.1-15.9 -208.3%   
Net profit margin %9.42.7 345.3%  
BALANCE SHEET DATA
Current assets Rs m66,968446,460 15.0%   
Current liabilities Rs m40,211325,519 12.4%   
Net working cap to sales %27.115.1 179.3%  
Current ratio x1.71.4 121.4%  
Inventory Days Days8384 99.7%  
Debtors Days Days8193 87.0%  
Net fixed assets Rs m33,322155,097 21.5%   
Share capital Rs m282426 66.3%   
"Free" reserves Rs m55,7700-   
Net worth Rs m56,052864,951 6.5%   
Long term debt Rs m35,738933,560 3.8%   
Total assets Rs m132,8882,320,136 5.7%  
Interest coverage x4.41.5 295.0%   
Debt to equity ratio x0.61.1 59.1%  
Sales to assets ratio x0.70.3 215.4%   
Return on assets %9.52.6 365.5%  
Return on equity %16.52.5 657.5%  
Return on capital %17.83.2 560.3%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m40,1400-   
CASH FLOW
From Operations Rs m13,242166,144 8.0%  
From Investments Rs m-6,990-85,878 8.1%  
From Financial Activity Rs m-7,387-77,399 9.5%  
Net Cashflow Rs m-2,9711,376 -215.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 70.95 Rs / USD

Compare GLENMARK PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare GLENMARK PHARMA With: CADILA HEALTHCARE  WYETH LTD  STERLING BIOTECH  ALEMBIC LTD  ELDER PHARMA  



Today's Market

Sensex Ends 95 Points Higher; Automobile and IT Stocks Witness Buying(Closing)

Indian share markets traded rangebound throughout the day and ended marginally higher. Sectoral indices ended on a mixed note with stocks in the automobile sector.

Related Views On News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound (Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival (Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market (The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound (The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Oct 23, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - GSK PHARMA COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS